CATALOGO DEI PRODOTTI DELLA RICERCA

TORTORA, GIAMPAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.455
EU - Europa 11.303
AS - Asia 8.846
SA - Sud America 1.070
AF - Africa 99
OC - Oceania 39
Continente sconosciuto - Info sul continente non disponibili 30
Totale 34.842
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.309
GB - Regno Unito 4.446
CN - Cina 3.593
SG - Singapore 3.505
RU - Federazione Russa 1.008
HK - Hong Kong 974
DE - Germania 969
IE - Irlanda 965
FR - Francia 942
BR - Brasile 941
SE - Svezia 938
IT - Italia 869
FI - Finlandia 678
VN - Vietnam 226
UA - Ucraina 155
NL - Olanda 91
KR - Corea 75
CA - Canada 72
JP - Giappone 72
IN - India 58
TR - Turchia 58
BE - Belgio 53
ID - Indonesia 50
MX - Messico 43
BD - Bangladesh 37
PL - Polonia 36
ZA - Sudafrica 34
AU - Australia 31
AR - Argentina 28
EU - Europa 27
AT - Austria 26
IQ - Iraq 24
UZ - Uzbekistan 23
IR - Iran 22
MA - Marocco 21
ES - Italia 20
SA - Arabia Saudita 19
CH - Svizzera 17
CL - Cile 17
EC - Ecuador 16
VE - Venezuela 16
PE - Perù 15
CO - Colombia 12
PY - Paraguay 12
AE - Emirati Arabi Uniti 11
AZ - Azerbaigian 11
KE - Kenya 10
CZ - Repubblica Ceca 9
LK - Sri Lanka 9
UY - Uruguay 9
IL - Israele 8
JO - Giordania 8
MY - Malesia 8
AL - Albania 7
CR - Costa Rica 7
EG - Egitto 7
LT - Lituania 7
LV - Lettonia 7
NP - Nepal 7
PH - Filippine 7
RO - Romania 7
BG - Bulgaria 6
GR - Grecia 6
KG - Kirghizistan 6
NZ - Nuova Zelanda 6
TN - Tunisia 6
EE - Estonia 5
JM - Giamaica 5
KZ - Kazakistan 5
PK - Pakistan 5
SK - Slovacchia (Repubblica Slovacca) 5
DK - Danimarca 4
HU - Ungheria 4
MK - Macedonia 4
NO - Norvegia 4
PT - Portogallo 4
TG - Togo 4
AO - Angola 3
BB - Barbados 3
BO - Bolivia 3
BY - Bielorussia 3
DZ - Algeria 3
GT - Guatemala 3
HN - Honduras 3
KH - Cambogia 3
LU - Lussemburgo 3
SN - Senegal 3
TH - Thailandia 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
CM - Camerun 2
DO - Repubblica Dominicana 2
IM - Isola di Man 2
MW - Malawi 2
PA - Panama 2
PS - Palestinian Territory 2
TT - Trinidad e Tobago 2
Totale 34.819
Salva come PNG Salva come JPEG
Città #
Southend 4.163
Chandler 1.850
Singapore 1.632
Jacksonville 1.437
Woodbridge 1.406
Dallas 1.288
Ann Arbor 1.008
Hong Kong 963
Dublin 962
Ashburn 671
Beijing 619
Houston 596
Lawrence 396
Princeton 396
Wilmington 379
Jinan 320
Nanjing 279
Shenyang 260
The Dalles 237
Verona 218
Munich 186
New York 186
Hebei 166
Los Angeles 161
Tianjin 157
Changsha 128
Nanchang 103
Columbus 100
Helsinki 100
Zhengzhou 96
Haikou 93
São Paulo 90
Ningbo 88
Sindelfingen 83
Milan 82
Hangzhou 81
Buffalo 80
Dong Ket 78
Guangzhou 78
Jiaxing 74
Santa Clara 68
Turku 66
Taizhou 60
Redwood City 58
Taiyuan 57
Tokyo 57
Norwalk 55
San Francisco 55
Brussels 53
Boardman 47
Seoul 47
Seattle 45
Lanzhou 43
Jakarta 42
Bologna 41
Chicago 39
Fuzhou 38
Lancaster 38
Falls Church 34
Frankfurt am Main 34
Dearborn 33
Brooklyn 32
Council Bluffs 30
Redmond 29
Ho Chi Minh City 28
Kent 28
Dongguan 26
Moscow 26
Warsaw 26
Washington 25
London 24
Rio de Janeiro 24
Nuremberg 23
Phoenix 23
Belo Horizonte 22
Hanoi 21
Johannesburg 21
Tashkent 21
Campinas 20
Rome 20
Stockholm 20
Toronto 20
Amsterdam 19
Düsseldorf 19
Fairfield 18
Mexico City 18
Augusta 17
Boston 17
Clearwater 17
Chennai 16
Charlotte 15
Curitiba 15
Montreal 15
Brasília 14
Porto Alegre 14
Sydney 13
Vienna 13
Salvador 12
San Mateo 12
Shanghai 12
Totale 23.085
Salva come PNG Salva come JPEG
Nome #
An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients 247
A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma 206
Whole-genome landscape of pancreatic neuroendocrine tumours 204
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status 201
Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment 186
True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs 178
BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing 176
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations 169
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 169
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 168
Genomic analyses identify molecular subtypes of pancreatic cancer 166
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report 164
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel 157
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling 157
Tumor thrombosis: a peculiar finding associated with pancreatic neuroendocrine neoplasms. A pictorial essay 155
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 150
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification 147
Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study 146
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 146
Reporting tumor molecular heterogeneity in histopathological diagnosis 145
Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors? 145
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 143
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 143
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 143
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis 143
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 141
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 140
Adenocarcinoma of the paraurethral glands: a case report 140
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma 138
FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. 133
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 133
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies 132
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Heat Shock Protein 90 Overexpression, Ki67 Proliferative Index, and Topoisomerase II-α Co-amplification as Predictors of Pathologic Complete Response to Neoadjuvant Chemotherapy With Trastuzumab and Docetaxel 132
Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies 131
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours 131
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 131
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis 131
Molecular Pathology of Pancreatic Cancer: from bench-to-bedside translation. 130
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study 130
Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance 130
A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration 129
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 129
Role of Combined Ga-68-DOTATOC and F-18-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors Implications for Managing Surgical Decisions 129
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas 128
Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer 128
Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment 127
The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome 127
HER2/neu Gene Determination in Women Screened for Breast Carcinoma: How Screening Programs Reduce the Skyrocketing Cost of Targeted Therapy 126
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 126
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases 126
A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts 125
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma 125
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 125
Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'? 125
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder 124
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 123
Evaluation of cell-free DNA as a biomarker for pancreatic malignancies 123
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 123
Current Strategies to Overcome Resistance to ALK-Inhibitor Agents 122
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 122
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. 121
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients 121
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach 121
Prognostication and response assessment in liver and pancreatic tumors: The new imaging 121
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients 120
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 120
Tumor seeding after percutaneous US-guided FNA of solid pancreatic neoplasms 119
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer 119
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 119
Profiling mTOR pathway in neuroendocrine tumors. 117
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer 117
Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage 117
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 116
Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo 116
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 115
R1507, the human monoclonal antibody targeting the Insulin-like Growth Factor Receptor (IGF-1R), in combination with cetuximab can reverse acquired resistance to cetuximab in pancreatic and colon cancer models 114
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study 114
Hypermutation In Pancreatic Cancer 114
ESGAR 2016 Book of Abstracts 114
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials 114
The development of PARP as a successful target for cancer therapy 113
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 112
8-Chloro-cAMP inhibits transforming growth factor alpha transformation of mammary epithelial cells by restoration of the normal mRNA patterns for cAMP-dependent protein kinase regulatory subunit isoforms which show disruption upon transformation. 112
Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis 111
Angiogenesis: A target for cancer therapy. 110
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 110
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 109
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes 108
Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy 108
The route to personalized medicine in bladder cancer: where do we stand? 108
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 108
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 108
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 108
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy 107
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. 106
AGENTI BIOLOGICI e CHEMIOTERAPICI: INTEGRAZIONE 106
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. 105
Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. 105
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 105
Selected news from the 2014 Genitourinary Cancers Symposium: translating novel strategies into clinical practice 105
Totale 13.182
Salva come PNG Salva come JPEG
Categoria #
all - tutte 134.422
article - articoli 122.059
book - libri 379
conference - conferenze 9.089
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.895
Totale 268.844
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.104 0 0 130 369 472 235 33 152 143 76 306 188
2021/20222.725 202 780 17 208 94 46 41 175 109 61 198 794
2022/20235.491 472 505 554 860 534 1.409 54 323 582 36 118 44
2023/20242.404 103 200 180 202 381 380 51 232 45 125 353 152
2024/20257.291 400 446 238 1.317 252 196 248 310 1.242 490 585 1.567
2025/20263.755 1.660 1.073 1.022 0 0 0 0 0 0 0 0 0
Totale 35.248